Endocrinology & Metabolism, 140(12), 5616-5621
Mor M, Kenley D
Each year, an estimated 300,000 adults in the United States die of causes related to obesity [2] According to the guidelines of the National Institute of Health (NIH) regarding the treatment of obesity, weight loss drugs approved by the FDA [US Food and Drug Administration] may only be used as part of a comprehensive weight loss program, including dietary therapy and physical activity, for patients with a BMI [body mass index] of 30 with no concomitant obesity-related risk factors or diseases, and for patients with a BMI of 27 with concomitant obesity-related risk factors or diseases[3].The risk factors and diseases considered important enough to warrant pharmacotherapy at a BMI of 27--29.9 are hypertension, dyslipidemia, coronary heart disease (CHD), type 2 diabetes, and sleep apnea [3]
The Mechanism of Action of AOD9604 AOD9604 primarily acts on adipose tissue (fat cells) through a specific mechanism: Targeted Lipolysis: Research suggests that AOD9604 stimulates the breakdown of stored fat (lipolysis) and inhibits lipogenesis (the formation of new fat), particularly in overweight individuals
& Herrmann, W
Semaglutide should not be used for the treatment of type 1 diabetes mellitus
